Descripción de la empresa
Arcus Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity focused on the development and commercialization of cancer therapies within the United States market. The company functions within the healthcare sector, specifically the biotechnology industry, where its operational scope is defined by the advancement of novel therapeutic candidates such as Casdatifan, a HIF-2a inhibitor for kidney cancer, and Domvanalimab, an anti-TIGIT antibody. This biotechnology firm currently employs 601 individuals and maintains a market capitalization of $2.77 billion, reflecting significant investor interest despite its pre-commercialization status. The annual revenue recorded over the trailing twelve months stands at $247.00 million, a figure that, when combined with the substantial market cap, indicates a company with a significant valuation relative to its current revenue generation, typical of firms investing heavily in research and development phases before generating substantial profits.
Salud financiera
The financial performance of Arcus Biosciences, Inc. over the trailing twelve months reveals a revenue of $247.00 million, a net income of -$353,000,000, and an EBITDA of -$376,000,000. The substantial gap between the reported revenue and the negative net income highlights a cost structure characterized by high operating expenses, likely driven by research, development, and commercialization costs that exceed total revenue generation. The company's free cash flow stands at -$162,250,000, indicating a cash outflow that limits immediate financial flexibility and suggests a reliance on external capital sources to fund ongoing operations and clinical trials. Margin analysis reveals a gross margin of -111.7%, an operating margin of -345.5%, and a profit margin of -142.9%; these deeply negative figures underscore the intense investment required to bring biopharmaceutical products to market before profitability is achieved. Regarding the balance sheet, the company holds $981.00 million in cash against $219.00 million in debt, resulting in a debt-to-equity ratio of 34.71, which suggests a leveraged position where cash reserves significantly outweigh current obligations. Short-term liquidity is robust, evidenced by a current ratio of 4.36, indicating that the company possesses ample current assets to cover its short-term liabilities without immediate distress. Finally, the return on equity is reported at -63.3% and the return on assets at -21.1%, metrics that reveal management is currently deploying capital to generate losses rather than returns, a common trajectory for clinical-stage companies yet one that signals the absence of positive shareholder value creation from operations at this stage.
Evaluación de valoración
Valuation metrics for Arcus Biosciences, Inc. present a complex picture due to the lack of profitability, with a P/E Ratio (TTM) listed as N/A and a forward P/E of -6.32. The distinction between a trailing P/E that cannot be calculated and a negative forward P/E implies that the market is pricing the stock based on future expectations of earnings turnaround rather than historical performance. The price-to-book ratio is recorded at 4.38, indicating that the market values the company at a significant premium over its book value, likely reflecting the intangible value of its intellectual property and pipeline potential rather than tangible assets. Alternative valuation metrics show a price-to-sales ratio of 11.20 and an EV/EBITDA of -5.33, suggesting that investors are willing to pay a high multiple of revenue to secure exposure to the company's biotechnology platform despite the negative earnings multiple. Technical price action shows a 52-week high of $26.40 and a 52-week low of $6.75, with the current trading price situated within this range but the specific percentage deviation from the high or low is not determinable without the real-time current price in the provided facts. The stock exhibits a beta of 0.86, which indicates that the price volatility of Arcus Biosciences is slightly lower than the broader market, suggesting somewhat lower sensitivity to general market fluctuations compared to the average stock.
Growth & Income
The growth profile of the company is defined by a revenue growth year-over-year of 26.9%, while earnings growth is listed as N/A due to the company's ongoing losses. Since earnings growth is not applicable, the expansion of revenue without corresponding profit growth implies that top-line expansion is currently outpacing any potential for earnings improvement, as the latter is constrained by the high fixed costs of drug development. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the firm reinvests all available cash flow back into its research and development activities rather than distributing income to shareholders. The overall growth and income profile is characterized by rapid revenue expansion in the absence of dividends or positive earnings, highlighting a strategy focused on capital appreciation through pipeline progression rather than current income generation.